Showing 1 - 20 results of 24 for search '"Pharmacoeconomics"', query time: 0.04s Refine Results
  1. 1

    PHARMACOECONOMICAL RESEARCH OF THE USE OF SORAFENIB IN MALIGNANT TUMORS by M. Y. Frolov, N. A. Avksentjev, I. G. Rusakov, E. V. Derkach

    Published 2016-09-01
    “…Pharmacoeconomic rationale for the use of sorafenib in this study is made by analyzing the impact on the budget. …”
    Get full text
    Article
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9

    The Antibiotic Puzzle: Guidelines for the Family Physician by G Harding, S Field, R MacMahon, T Louie, Prairie Consensus Conference Group

    Published 1997-01-01
    “…New drugs and new classes of antibiotics are being developed and made available, and emerging resistance and pharmacoeconomics play important roles. The Canadian healthcare system presents a unique challenge for prescribing physicians because pharmacoeconomic considerations are becoming increasingly important. …”
    Get full text
    Article
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    Reliability and validity of the Lithuanian version of headache-attributed lost time (HALT) index by I. Zagorskienė, E. Abelkis, R. Mameniškienė

    Published 2018-03-01
    “…The questionnaire was culturally adapted for Lithuanian speaking population following the recommendations of International Society for Pharmacoeconomics and Outcomes Research. Psychometric properties of HALT were tested on adults complaining of headache of any kind. …”
    Get full text
    Article
  15. 15

    Tackling Extended Hospital Stays in Patients with Acute Bacterial Skin and Skin Structure Infections by Gavin Barlow, Michael Wilke, Guillaume Béraud

    Published 2022-09-01
    “… Hospitalisation rates for acute bacterial skin and skin structure infection (ABSSSI) are rising and represent a large pharmacoeconomic burden as treatment may involve an extended number of days of antibiotic therapy. …”
    Get full text
    Article
  16. 16

    Methods to appraise available evidence and adequacy of data from a systematic literature review to conduct a robust network meta-analysis of treatment options for patients with hos... by Laura Puzniak, Ryan Dillon, Thomas Lodise

    Published 2023-01-01
    “…We aimed to determine if available evidence from a previously conducted systematic literature review was sufficient to conduct a robust network meta-analysis (NMA) using the International Society for Pharmacoeconomics and Outcomes Research Good Practice Task Force NMA study questionnaire to evaluate suitability, relevance, and credibility of available randomized-controlled trials (RCT) of antibacterial therapies for treatment of patients with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP). …”
    Get full text
    Article
  17. 17

    Translation and Cultural Adaptation of the ISTH-Bleeding Assessment Tool to European Portuguese by Diana Carneiro-Leão, Sofia Teixeira, Rita Queirós Pereira, Teresa Mota, Manuela Lopes, Susana Nobre-Fernandes, Fernando Araújo

    Published 2025-02-01
    “…Methods: The translation and cultural adaptation were based on the International Society for Pharmacoeconomics and Outcomes Research Guidelines and initiated after obtaining permission from the authors. …”
    Get full text
    Article
  18. 18
  19. 19

    Cost-effectiveness analysis of gumarontinib versus savolitinib for the treatment of advanced or metastatic NSCLC with MET exon 14 skipping mutations in China using partitioned surv... by Gang Fang, Zhipeng Pi, Yiping An, Xinxin Cao, Wei Li, Wei Li, Xiangjun Zhu, Jinxi Ding, Jinxi Ding

    Published 2025-01-01
    “…However, the comparison of their efficacy and pharmacoeconomics profiles remains limited. This study aims to evaluate the cost-effectiveness of gumarontinib versus savolitinib for the treatment of METex14 skipping NSCLC in China.MethodsA 3-state partitioned survival model (PSM) was developed with lifetime horizon from the perspective of Chinese healthcare system. …”
    Get full text
    Article
  20. 20